"ow do we (i) treat VTE once a diagnosis is confirmed? (ii) assess the risk of VTE, and (iii) manage women with a high risk of VTE? When anticoagulants are required in pregnancy and the puerperium, low-molecular-weight heparin (LMWH) is now the preferred drug, but optimal dosage and monitoring remain unresolved issues. In addition, there is a paucity of reliable information about the risk of VTE in women with thrombophilia (asymptomatic or with a previous deep venous thrombosis or pulmonary embolism). Recommendations and limitations of the literature are highlighted. INTRODUCTION Pulmonary "

Full text